Lucid Diagnostics

#Esophageal cancer #Barrett's esophagus #Gastroesophageal reflux disease #Early cancer detection

Lucid Diagnostics is a commercial-stage cancer-prevention diagnostics company focused on early detection of esophageal precancer and cancer in patients with chronic gastroesophageal reflux disease. Its EsoGuard esophageal DNA test is run on samples collected non-invasively with the EsoCheck cell collection device, and the company operates a CLIA-certified, CAP-accredited laboratory. Lucid is a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Company Info

Sector:Diagnostics / Cancer Prevention

Headquarters:New York, New York, USA

Founded:2018

Website:www.luciddx.com/

Clinical Development Pipeline

EsoGuard Esophageal DNA Test

Target: Esophageal DNA methylation markers

Detection of esophageal precancer and cancer

Preclinical

Phase 1

Phase 2

Phase 3

Approved

EsoCheck Cell Collection Device

Target: Device - targeted cell collection

Non-invasive esophageal cell sampling

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Lishan Aklog, MD

Chairman & Chief Executive Officer

Dennis M. McGrath

Chief Financial Officer

Careers & Job Openings

See all open roles

Various

USA

Apply Now →